Li ZH, Yang GH, Wang F. Molecular mechanisms of Baihedihuang decoction as a treatment for breast cancer related anxiety: A network pharmacology and molecular docking study. World J Clin Cases 2022; 10(33): 12104-12115 [PMID: 36483797 DOI: 10.12998/wjcc.v10.i33.12104]
Corresponding Author of This Article
Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Street, Chaoyang District, Beijing 100102, China. wf074500@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 26, 2022; 10(33): 12104-12115 Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12104
Molecular mechanisms of Baihedihuang decoction as a treatment for breast cancer related anxiety: A network pharmacology and molecular docking study
Zhong-Hui Li, Guo-Hua Yang, Fang Wang
Zhong-Hui Li, Guo-Hua Yang, Fang Wang, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China
Author contributions: Li ZH wrote the manuscript; Yang GH and Wang F provided key comments and revised the manuscript; all authors approved the final manuscript.
Conflict-of-interest statement: All authors declare that there is no conflict of interest regarding the publication of this paper.
Data sharing statement: Technical appendix, statistical code, and dataset available from the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fang Wang, MD, Chief Doctor, Department of Oncology, Wangjing Hospital, China Academy of Chinese Medical Sciences, No. 6 Huajiadi Street, Chaoyang District, Beijing 100102, China. wf074500@163.com
Received: July 15, 2022 Peer-review started: July 15, 2022 First decision: August 21, 2022 Revised: September 4, 2022 Accepted: October 12, 2022 Article in press: October 12, 2022 Published online: November 26, 2022
Core Tip
Core Tip: Baihedihuang decoction (BD) has significant effects on breast cancer related anxiety; however, its molecular targets in this condition remain unknown. We conducted a network pharmacology and molecular docking study to determine whether BD ingredients target molecules and signaling pathways related to breast cancer related anxiety pathogenesis. The main active ingredients identified include verbascoside, β-sitosterol, stigmasterol, and catalpol. Target genes included CDK2, TP53, HTR2A, and ESR1, which are involved in cell cycle, apoptosis, cell autophagy, blood circulation, and other biological processes. Our results confirm that BD can treat breast cancer related anxiety through multi-component, multi-target, and multi-channel synergy.
